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Abstract: The central nervous system of adult mammals has long been considered as a complex static
structure unable to undergo any regenerative process to refurbish its dead nodes. This dogma was
challenged by Altman in the 1960s and neuron self-renewal has been demonstrated ever since in many
species, including humans. Aging, neurodegenerative, and some mental diseases are associated
with an exponential decrease in brain neurogenesis. Therefore, the controlled pharmacological
stimulation of the endogenous neural stem cells (NSCs) niches might counteract the neuronal loss
in Alzheimer’s disease (AD) and other pathologies, opening an exciting new therapeutic avenue.
In the last years, druggable molecular targets and signalling pathways involved in neurogenic
processes have been identified, and as a consequence, different drug types have been developed and
tested in neuronal plasticity. This review focuses on recent advances in neurogenic agents acting
at serotonin and/or melatonin systems, Wnt/β-catenin pathway, sigma receptors, nicotinamide
phosphoribosyltransferase (NAMPT) and nuclear erythroid 2-related factor (Nrf2).
Keywords: adult neurogenesis; serotonin system; melatonin receptors; Wnt/β-catenin pathway;
sigma receptors; nicotinamide phosphoribosyltransferase; nuclear erythroid 2-related factor
1. Introduction
Regenerative medicine is one of the most innovative therapeutic approaches for the treatment of
different pathologies. Undoubtedly, it will be a mainstay of the future medicine, although nowadays
there are still several obstacles to overcome. One of these challenges is the development of therapies
for the central nervous system (CNS). Efficient regeneration of damaged tissues by an accident
(e.g., trauma, stroke), by neurodegenerative diseases (e.g., AD, Parkinson) or psychiatric conditions
(e.g., mood disorders, anxiety, major depression) would be a great advance to achieve the definitive
cure for these diseases [1]. Indeed, the discovery of the existence of neural stem-cells (NSCs) niches in
the adult human brain opens the door to the development of small molecules as restorative therapies
for such pathologies. Ideally, such medicines should be taken orally and must reach the brain for
promoting endogenous auto-repair processes. This strategy is simpler than the implant of pluripotent
cells and advantageously avoids the ethical dilemma of the employment of human embryonic NSCs [2].
The generation of new neuronal cells in the brain of vertebrates is an essential process throughout
the lifetime of the individual. Although for a long time, neurogenesis was thought to be restricted to
the first stages of embryonic development, this concept was challenged in 1962 when Altman showed
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the formation of new neurons in the brain of adult rats [3]. In subsequent years, this process was
described in adult birds [4], rabbits [5], marsupials [6] and primates [7].
However, the therapeutic potential of neurogenesis only began to gain strength in the 1990s
with the discovery of two niches containing self-renewing NSCs in the adult murine brain [8–11]:
the subventricular zone (SVZ), lining the lateral ventricles, and the subgranular zone (SGZ) in the
dentate gyrus (DG) of hippocampus [12]. The definitive demonstration of the existence of neurogenic
processes in the adult human brain was made by Eriksson et al. in 1998, through the examination of
post-mortem hippocampal tissues from patients who had been treated with the thymidine analogue
bromodeoxyuridine (BrdU) [13], which is commonly used in the detection of proliferating cells in
living tissues [14]. These studies demonstrated that the hippocampus is able to develop and integrate
new neuronal bodies during adult life, beyond the embryonic development [15].
Embryonic and adult neurogenesis share many transcriptional regulators but display significant
differences in their modulation. During the early development, neurogenesis is vast and occurs in a
coordinated manner to generate the CNS as the leading machinery of the whole organism, whereas
in adulthood neurogenesis is restricted to certain neurogenic niches. Adult NSCs have additional
and more advanced modulatory mechanisms, by means of which NSCs can supply specific types of
neurons to limited areas of the CNS [16–18]. The quantitative differences between embryonic and
adult neurogenesis reveal that the post-natal homeostatic function of the brain is rather conservative
and does not require major renovations of the neural network for its normal functioning [17]. However,
under ischemic conditions, it has been shown that neurogenesis occurs beyond DG and SVZ in adult
rats by activation of neuronal progenitor cells in the neocortical layer 1 [19]. Thus, it could tentatively
differentiate between a physiological adult neurogenesis in the DG and SVZ and a restorative
neurogenesis in larger regions of the CNS, triggered under pathological conditions derived from
hypoxic episodes.
Adult neurogenesis is sequential: activation of quiescent NSCs and proliferation, migration to
different areas of the CNS, differentiation and maturation to specific cell types, and integration in
the brain circuitry [20]. In lower vertebrates the neurogenic process is widely extended in the CNS,
whereas in animals with higher neuronal complexity is restricted to the few above-mentioned regions,
where the multipotent NSCs generate new neurons and glia cells throughout the individual’s life [21].
The hippocampus is a part of the limbic system that plays important roles in the consolidation of
information from short-term to long-term memory [22]. Although the relevance of neurogenesis in the
adult hippocampus remains to be determined, some reports link it to learning processes and memory
integration [23,24]. Neurogenesis in the DG is dynamic and sensitive to physiological, pathological and
pharmacological stimuli [25]. For instance, aging, neurodegeneration, and some mental diseases are
associated with an exponential decrease in hippocampal neurogenesis [24]. Therefore, the controlled
pharmacological stimulation of the endogenous NSCs from neurogenic niches might counteract the
age-related loss of memory and cognitive deterioration in pathological conditions [26].
Since the discovery of the adult neurogenesis, much research effort has been devoted to
study its mechanisms and implications in healthy and pathological conditions. Some elucidated
neurogenic mechanisms involve neurotransmitters (such as dopamine, glutamate, and serotonin),
hormones (such as thyroid hormones and melatonin), signalling pathways (Notch, Wnt/β-catenin,
NAMPT-NAD, etc.), transcription factors (Sox-2, the orphan nuclear receptor TLX, Nrf2, etc.),
growth factors (brain-derived neurotrophic factor BDNF, insulin-like grow factor-1, fibroblast growth
factor 2, etc.) and epigenetic factors (reviewed in [27]). The above findings have led to the discovery of
a significant amount of small-molecules able to take part in neuronal renewal and plasticity [28–32].
As an example, in the last five years around 700 reviews on “adult neurogenesis” have been published,
as countered from PubMed. The present review only modestly attempts to have a glance in some recent
advances in neurogenic small molecules acting at serotonin and/or melatonin systems, Wnt/β-catenin
pathway, sigma receptors, nicotinamide phosphoribosyltransferase (NAMPT) and nuclear erythroid
2-related factor (Nrf2).
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2. Role of Serotonergic System in Neurogenesis
Serotonin (5-hydroxytryptamine, 5-HT, Figure 1) is crucial for the normal brain development and
plays an important role in the CNS over lifetime [33]. This neurotransmitter is involved in almost
every adaptive response, such as appetite and mood, and in a great number of cognitive functions.
Up to 15 subtypes of serotonin receptors (5-HTRs) mediate the serotonergic tone, both in the central
and peripheral nervous system [34]. In relation to neurogenic processes, several studies demonstrated
the involvement of serotonergic system in NSC’s proliferation and maturation to a neural phenotype.
Brezun and Daszuta showed that serotonin deficits in adult rats are associated with decreased adult
neurogenesis in the DG and SVZ [35]. It has been demonstrated its necessity in synaptogenesis [36]
and more recently, its importance in developing-axon guidance [37].
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In in vitro experiments, Benninghoff et al. found that serotonin depletion hinders the survival
and proliferation of NSC-neurospheres derived from adult mo s hippocampus. By selectively
antagoniz g differ nt 5-HTRs, these au hors demonstrated that the neurogenic actions of serotonin
i NSCs were mediated by the 5-HT1A subtype and, to lesser extent, through the 5-HT2CR [38].
These findings, together with the observation that increased levels of s rotonin have positive effects on
neurogenesis and axonal growth, has e cour ged the study of agonists at s veral 5-HTR subtypes as
well as selective serotonin reuptake in ibitors (SSRIs) as n urogenic agents, both in vitro and in vivo
models with interesti g results.
Several in vivo s udies demonstrated the implication of the 5-HT1A receptor subtype in neurogenic
processes. Grabiec et al. studied the effect of the 5-HT1A agonists buspirone (8-[4-(4-pyrimidin-
2-ylpiperazin-1-yl)butyl]-8-azaspiro[4,5]decane-7,9-dione) and 8-OH-DPAT (8-hydroxy-2-(di-n-
propylamino)tetralin, Figure 1), i comparison with the 5-HT1A antagonist WAY100635 (N-[2-[4-(2-
m thoxyph nyl)-1-piperazinyl]ethyl]-N-(2-pyridyl)cyclohexanecarboxamide) in Monodelphis domestica
(a small South Amer can marsupial, als named opossum). Compounds were injected during seven
successive days and animals were sacrifice two months later. Auth rs found that the 5-HT1A agonists
(buspirone and 8-OH-DPAT) increased the number of newly generated neuronal cells, whereas the
ant gonist WAY100635 reduced them. Moreover, these 5-HT1A agonists stimulated the d fferentiation
of NSCs mainly into neurons (55%–76%), while a lower prop rtion was tr nsformed into astrogl a
(6%–12%) [39]. Beh vioural experiments in the opossums treate with 5-HT1A agonists d monstrated
that the major number of new neurons correlated with better cognitive performance in a t st for
detecting hidden food based on olfactory perception [40].
Fluoxetine (N-met yl-3-phenyl-3-[4-(trifl oromethyl) henoxy]propan-1-amine, Figure 1), better
know by its commercial name Prozac®, is a SSRI used as antidepressant for the treatment of
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major depression, obsessive-compulsive disorder, and bulimia, among other psychiatric diseases.
Recent studies conducted in a mouse model of Down syndrome showed that treatment with
fluoxetine during the embryonic period rescued overall brain development and that neonatal
treatment induced full recovery of hippocampal neurogenesis, dendritic development, connectivity and
hippocampus-dependent memory [41,42]. The effects of either the pre- or early postnatal treatments
were retained in adolescence and adult life stages, showing that the early treatment with fluoxetine
enduringly restores cognitive impairment and prevents early signs of AD-like pathology [42].
Rivastigmine [(S)-3-[1-(dimethylamino)ethyl]phenyl N-ethyl-N-methylcarbamate, Figure 1] is
used to treat mild to moderate dementia in AD. It acts as a non-competitive inhibitor of both
acetylcholinesterase (AChE) and butylcholinesterase (BuChE), which improves cognitive functions by
increasing acetylcholine levels at the synaptic cleft. Moreover, rivastigmine ameliorates depression-like
symptoms in patients by mechanisms that are not fully understood [43]. Recently, it has been observed
that after administration of rivastigmine to olfactory bulbectomized (OBX) mice, hippocampal
neurogenesis increased along with enhanced levels of protein kinase B (PKB), and extracellular
signal-regulated kinase (ERK) phosphorylation. The ability of rivastigmine to rescue 5HT1AR levels in
hippocampus appears to underlie such effects [44,45].
Pinoline (6-methoxy-1,2,3,4-tetrahydro-9H-pyrido[3,4-b]indole, Figure 1) is a tricyclic β-carboline
and a conformationally-restricted analogue of the serotonin derivative 5-methoxy-tryptamine
(5-MeOT). Pinoline is a modest inhibitor of monoaminoxidase A and a potent oxygen radical scavenger.
It also activates 5-HTRs, being a full agonist at the 5-HT2C subtype and a partial agonist at the 5-HT2AR.
Trace concentrations of pinoline (10 nM) were found to stimulate early differentiation and neuronal
maturation of primary cultures of NSC derived from the rat SVZ [46]. Its potent neurogenic properties
in vitro correlate with its serotonergic agonism.
3. Melatonergic System Role in Neurogenesis
Melatonin [N-(2-(5-methoxy-1H-indol-3-yl)ethyl)acetamide, Figure 2] is a neurohormone
produced primarily in the pineal gland. Two G-protein-coupled receptors (GPCRs), namely MT1
and MT2 (MT1R and MT2R) [47,48] mediate most of the vast physiological and pharmacological
actions of melatonin, such as the regulation of circadian and seasonal rhythms’, immune and
endogenous antioxidant systems, among others [49]. Melatonin is a potent free-radical scavenger
and a wide-spectrum antioxidant [50,51], improves mitochondrial energy metabolism [52], decreases
neurofilament hyperphosphorylation and plays a neuroprotective role against beta-amyloid peptide
(Aβ) [53]. Moreover, the long-term oral administration of melatonin improves learning and memory
in the AD-model APP/Ps1 transgenic mouse [54].
Melatonin plasma levels decline along with age in a similar manner as the neuronal self-renewal
rate does [55]. Whether both phenomena are related or not is still unclear, although melatonin has
been reported to positively modulate neurogenesis, as recently reviewed by several authors [56–59].
Exogenous administration of melatonin increases precursor cell survival in hippocampus of mice,
promotes neuronal differentiation [60], and stimulates the maturation and complexity of dendrites in
the newly formed neurons [61]. Its chronic administration increases the cell proliferation rate and delays
the decline of neurogenesis in the hippocampus of adult mice [62]. These data are in agreement with
previous observations in different mice strains that concluded that exogenous melatonin administration
delays the onset of poor health states prior to death and ameliorates the process of aging, including a
much better cognitive performance [63]. The term ‘Methuselah syndrome’ was appropriately coined
to summarize the health-preserving properties of melatonin. Over the past years, many scientific
papers have focused on the neurogenic properties of melatonin-related compounds in both in vitro
and in vivo murine models [64–66].
N-Acetylserotonin [N-(2-(5-hydroxy-1H-indol-3-yl)ethyl)acetamide, Figure 2] is the immediate
precursor of melatonin. Until recent years, it was thought to lack any relevant biological activity by
itself. However, its distribution in some brain areas where serotonin and melatonin are absent, suggests
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that it may have other physiological roles [67]. Besides its MT1/MT2 agonism, N-acetylserotonin
has been shown to act as a potent agonist at the tyrosine receptor kinase (TrkB) receptor, whereas
serotonin and melatonin do not [67,68]. TrkB belongs to a family of tyrosine kinases that regulates
neuronal survival and neural plasticity in the mammalian nervous system. TrkB binds the brain-derived
neurotrophic factor (BDNF) with high affinity, triggering signalling pathways that regulate long-term
potentiation (LTP), neurogenesis and neuronal plasticity [69,70]. TrkB blockade abolished the effects
of N-acetylserotonin on neural cell proliferation, thus suggesting the key role of TrkB on the positive
effects of N-acetylserotonin in adult mice neurogenesis [71].
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Agomelatine (N-[2-(7-methoxynaphthalen-1-yl)ethyl]acetamide, Figure 2), marketed as Valdoxan®
for the treatment of major depression in adults, shows a mixed profile (MT1/MT2 agonism and
5-HT2C antagonism). Agomelatine was found to positively affect all stages of neurogenesis in rat
hippocampus under normal or stress conditions [72,73]. Banasr et al. found that chronic administration
of agomelatine (21 days) increased NSCs proliferation and maturation in the hippocampal DG, in
contrast with acute (4 h) or subchronic (7 days) treatments [74]. In an effort to elucidate the neurogenic
mechanisms of agomelatine, Soumier et al. found that this drug increased the ratio of mature vs.
immature neurons and also promoted neurite outgrowth, probably through the BDNF up-regulation
subsequent to MT1/MT2 stimulation [75].
Recently, several melatonin-based compounds have been tested in primary hippocampal NSCs
of adult rats. A family of melatonin–N,N-dibenzyl(N-methyl)amine hybrids (Figure 2), showing a
balanced multifunctional profile covering antioxidant, cholinergic and neuroprotective properties,
was found to stimulate NSCs proliferation and the subsequent maturation into a neuronal phenotype.
Some hybrids protected neuronal cells against mitochondrial oxidative stress and were 2-fold more
potent than melatonin as neurogenic agents [76].
N-Acetyl bioisosteres of melatonin were recently obtained by replacing the acetamido group of
the natural product by a series of reversed amides and azoles (Figure 2). Several of these melatonin
bioisosteres promoted differentiation of rat neural stem cells to a neuronal phenotype in vitro, in some
cases with greater potency than melatonin itself. In the case of the melatonin-based compounds derived
from 1,3,4-oxadiazole and 1,3,4-oxadiazol-2-one, their neurogenic effects were almost completely
blocked by luzindole [N-(2-(2-benzyl-1H-indol-3-yl)ethyl)acetamide], a non-selective MT1R/MT2R
antagonist. These results evidenced the key implication of melatonergic receptors in the neurogenic
properties of these compounds, although the participation of additional signalling pathways cannot be
excluded [77].
Melatonin and pinoline hybrids with β- and γ-carboline scaffolds retained the neurogenic
properties of the parent compounds in an in vitro model of neural stem cell differentiation. The
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orthodox melatonin–pinoline hybrid (Figure 2) displayed partial melatonergic agonism, with a slight
preference for the MT2R subtype, and promoted early differentiation and neuronal maturation in
in vitro experiments. These effects are likely mediated by melatonergic stimulation [46].
4. Effects of the Wnt/β-Catenin Pathway in Neurogenesis
The canonical Wnt/β-catenin pathway displays important roles in both embryonic
CNS-development and adult brain self-repairing processes [78]. During embryonic growth,
Wnt signalling is essential for the appropriate formation of hippocampus and cortex [79], whereas in
the adult brain it regulates neurogenesis and synaptic plasticity [80].
Modulation of adult neurogenesis by Wnt pathway was demonstrated in vivo by Lie et al.
Blockage of the Wnt signalling reduced NSC proliferation and maturation in the SGZ in rats,
whereas Wnt activation improved neurogenic processes [81]. Moreover, Jessberger et al. revealed
that Wnt-mediated neurogenesis contributes to hippocampal memory functions, as Wnt blockade
produced impaired long-term spatial memory and object recognition in adult rats [82].
The enzyme glycogen synthase kinase-3β (GSK-3β) is an important component of the
Wnt/β-catenin pathway, which phosphorylates β-catenin and modifies the signalling cascade that
finally modulates adult neurogenesis. Interestingly, Eom and Jope reported a drastic neurogenic drop
in the GSK-3α/β knock-in mouse, compared with the wild-type [83]. Thus, GSK-3β overexpression
was found to provoke neuronal death and to diminish the NSC proliferative rate in the hippocampal
DG by a depletion of neurogenic niches [84]. Therefore, the inhibition of GSK-3β and subsequent
activation of Wnt/β-catenin signalling pathway could promote hippocampal neurogenesis, as shown
in the following examples.
Wexler et al. found that the mood stabilizer lithium, also known as a potent GSK-3β inhibitor,
induced the proliferation and differentiation of adult hippocampal progenitor cells in primary cell
cultures. The positive effects of lithium on neurogenic processes were found to be independent of
inositol depletion, but linked to GSK-3β inhibition and β-catenin activation [85]. Dastjerdi et al.
demonstrated that 6-bromoindirubin-3’-oxime (BIO, Figure 3), a specific GSK-3β inhibitor and Wnt
activator, increased the expression of the early neurogenic marker β-III-tubulin in unrestricted somatic
stem cells, pointing out that GSK-3β inhibition enhanced their neural differentiation [86].
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The in vivo confirmations of the above results were made in murine models of stress, depression,
and toxic conditions, as well as in models of neurodegenerative diseases, such as AD. In pre-pubertal
and adult rats subjected to chronic-mild-stress, Silva et al. observed that lithium treatment improved
behavioural, hormonal, and neurogenic turnover in the SVZ [87]. These authors also reported
that inhibition of GSK-3β by the thiazolyl-benzyl urea AR-A014418 [1-(4-methoxybenzyl)-3-(5-
nitrothiazol-2-yl)urea, Figure 3] yielded higher levels of the presynaptic protein synapsin-I (a known
target of GSK-3β), which in turn alleviated stress effects and neurogenic depletion.
Valproate (2-propylpentanoate, Figure 3) is a well-known drug, used to the treatment of epilepsy,
bipolar disorders and migraine. Despite its complex polypharmacology, some studies reported that
valproate promotes β-catenin pathway trough GSK-3β inhibition [88] and more recently, that it
recovered the proliferation rate of neural precursor cells in the DG in a rat model of depression [89].
Fujimura and Usuki showed that low concentration of methylmercury (MeHg, 10 nM) suppressed
the proliferation of neural progenitor cells of rat cortical tissues. These effects were reversed
by GSK-3β inhibitors, such as lithium and the maleimide derivative SB-415286 [3-((3-chloro-4-
hydroxyphenyl)amino)-4-(2-nitrophenyl)-1H-pyrrole-2,5-dione, Figure 3], by a mechanism that
involved the blockade of cyclin E degradation [90].
Fiorentini et al. reported that lithium treatment improved hippocampal neurogenesis and
cognition functions in the double transgenic CRND8 mice, an AD-model that develop early plaque
formation [91]. Andrographolide (3-[2-(decahydro-6-hydroxy-5-hydroxymethyl-5,8a-dimethyl-2-
methylene-1-napthalenyl)ethylidene]dihydro-4-hydroxy-2(3H)-furanone, Figure 3), a diterpenoid
isolated from Andrographis paniculata, has been intensely studied in cell signalling pathways and shows
neuroprotective effects in different models of oxidative damage [92]. In the APPswe/PS1∆E9 mouse
model of AD, this terpenoid improved the consolidation of LTP against the damage induced by Aβ
oligomers, most likely by inhibiting GSK-3β [93]. Moreover, andrographolide promoted proliferation
of neural progenitor cells and the generation of new neurons in the adult hippocampus of wild-type
and APPswe/PS1∆E9 mice, by stimulation of the Wnt/β-catenin signalling pathway [94].
Using rat NSCs neurosphere cultures, several GSK-3β inhibitors were tested as neurogenic agents,
namely thiadiazolidine-3,5-diones, thiazolyl-benzyl ureas and indolyl-maleimides [95]. These diverse
small molecules are related to tideglusib [4-benzyl-2-(naphthalen-1-yl)-1,2,4-thiadiazolidine-3,5-dione],
which reached phase II in clinical trials for AD [96], AR-A014418 and SB-415286, respectively (Figure 3).
Morales-García et al. showed that these GSK-3β inhibitors increased the number, migration, and
differentiation ability of NSCs in in vitro experiments. Moreover, in adult male Wistar rats the
oral administration of tideglusib positively affected the neuronal proliferation in SGZ and hilus,
dendritic arborisation and neuroblasts’ migration [95].
More recently, Prati et al. described triazin-ones and -thiones (Figure 3) as dual inhibitors of both
BACE-1 and GSK-3β that also displayed effective neurogenic activities in neurosphere cultures of
primary NSCs from rats [97,98]. The most active neurogenic agents were found to be triazinones with
R = H, ethyl, and n-propyl (Figure 3), which significantly increased the number of cells reaching a
mature neuronal state as shown by immunostaining with MAP2.
5. Sigma Receptors Role in Neurogenesis
Sigma receptors (σRs) appear to be involved in numerous biological functions, including cell
survival. They were originally misclassified as a subtype of opioid receptor in the 1970s, but σRs are
currently considered as a unique type of intracellular proteins, different from GPCRs and ionotropic
receptors. In humans, σRs and in particular the subtype-1, are expressed in regions of the CNS related
to motor, emotional, and cognitive functions: hippocampus, cerebral cortex, substantia nigra, DG of
hippocampus and cerebellum [99,100]. Interestingly, adult σ1R knockout mice show a depressive-like
phenotype and a reduced neurogenic turnover in the DG [101]. Moreover, a significant reduction in the
overall levels of the σ1R protein has been recently reported in the AD-brains [102] and in the lumbar
spinal cord of patients suffering amyotrophic lateral sclerosis (ALS) [103].
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It has been also demonstrated that the activation of σ1R elicits neuroprotection by
different mechanisms: modulation of voltage-dependent calcium channels involved in calcium
homeostasis [104]; attenuation of the production of reactive oxygen and nitrogen species, mainly
through the modulation of endogenous antioxidant proteins [105,106]; and preservation of
mitochondrial function in ischemic stress conditions, by increasing mitochondrial respiration and ATP
synthesis [107].
In addition to the above-mentioned neuroprotective properties, activation of σ1R has also positive
effects on neurogenic processes and dendritic outgrowth. Thus, several σ1R agonists of natural origin
have been probed, such as DHEA (dehydroepiandrosterone) and myristic acid (tetradecanoic acid),
or from pharmaceutical design, such as fluvoxamine (2-{[(E)-{5methoxy-1-[4-(trifluoromethyl)phenyl]
pentylidene}amino]oxy}ethanamine), SA-4503 (1-[2-(3,4-dimethoxyphenyl)ethyl]-4-(3-phenylpropyl)
piperazine), or lipoic acid-donepezil derivatives (Figure 4).
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DHEA is an endogenous neuroactive steroid derived from cholesterol that is secreted by adrenal
glands, gonads and CNS-cells, and whose blood levels decrease along age [108,109]. The DHEA
age-dependent decline could be linked to the onset of age-related cognitive deficits, such as AD [110],
and this fact has prompted its study in several murine models of neurodegenerative diseases.
In OBX mice, the σ1R stimulation by DHEA ameliorates depressive-like behaviours and cognitive
impairments [111] and these effects are associated with improved hippocampal neurogenesis in
the DG through the activation of PKB/GSK-3β/β-catenin pathway [112]. DHEA is also found to
stimulate dendritic arborisation and neurite outgrowth by increasing the expression of the glial
cell-derived neurotrophic factor (GDNF) [113,114], thus promoting the formation of new connections
in neuronal plasticity.
Myristic acid (Figure 4) is a saturated fatty acid, isolated from Myristica fragrans nuts, with σ1R
agonistic properties. Tsai et al. found that σ1R activation by myristic acid regulates the correct tau
phosphorylation and promotes axon elongation [115].
Since several studies found that adult neurogenesis is impaired in models of depression, a number of
antidepressants have been tested as neurogenic agents [116]. Fluvoxamine is a marketed SSRI that also
displays a potent agonism atσ1R, in the nanomolar range [117]. This antidepressant was found to potentiate
nerve-growth factor (NGF)-induced neurite outgrowth in PC12 cells, an effect that was blocked by the σ1R
antagonist NE-100 [4-methoxy-3-(2-phenylethoxy)-N,N-dipropylbenzeneethanamine], pointing out the
involvement of σ1R in the neuroplasticity actions of fluvoxamine [118].
Further research was performed on the neurogenic effects of σ1R agonists, namely fluvoxamine
and SA-4503, in calcium/calmodulin-dependent protein kinase IV (CaMKIV)-null mice, which exhibit
depressive-like behaviours and impaired neurogenesis. The chronic stimulation of σ1R by treatment
with the above-mentioned σ1R agonists increased hippocampal neurogenesis, improving induction
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and maintenance of hippocampal LTP. Such effects are closely related with the improvement of
depressive-like behaviours in CaMKIV-null mice [119].
Recently, a lipoic acid–N-benzylpiperine hybrid (Figure 4) was evaluated in primary hippocampal
NSCs of adult rats. This nanomolar σ1R agonist induced the expression of early neurogenesis markers
and also promoted neuronal maturation [120], probably mediated by σ1R stimulation.
6. Role of NAMPT-NAD in Neurogenesis
Nicotinamide phosphoribosyl transferase (NAMPT) is the rate limiting-enzyme in the biosynthesis
of nicotinamide adenine dinucleotide (NAD), an important coenzyme in cellular metabolism and
mitochondrial energy production. NAMPT is mainly expressed in nucleus and cytoplasm, although it
can be also found in the extracellular space. Its wide distribution and its decisive role in mitochondrial
biogenesis indicate that NAMPT plays important functions in the cellular metabolism [121].
Regarding neurogenesis, NAMPT is particularly important in the proliferation and differentiation
of NSCs. Some consequences of NAMPT inactivation or complete ablation include impairment of
NSCs’ proliferation and self-renewal, as well as diminished NSC-mediated oligodendrogenesis [122].
Under aging conditions, NAMPT and NAD levels are considerably reduced in hippocampus, along
with NSCs. These age-related reductions and their associated serious consequences in mitochondrial
metabolism suggest that NAMPT activation could be a good therapeutic intervention to increase
survival and function of NSCs [123].
Recently, a family of NAMPT activators has been described with interesting neuroprotective
and proneurogenic effects. The aminopropyl carbazole P7C3 [1-(3,6-dibromo-9H-carbazol-9-yl)-
3-(phenylamino)propan-2-ol, Figure 5], which was emerged from an in vivo neurogenic screen of 1000
small molecules, improved proliferation and survival of newborn neurons in the hippocampal DG,
protected mitochondrial membrane integrity, and ameliorated cognitive decline in aged rats [124].
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Based on the aminopropyl carbazole scaffold, many P7C3 derivatives were developed
(i.e., P7C3-A20, N-(3-(3,6-dibromo-9H-carbazol-9-yl)-2-fluoropropyl)-3-methoxyaniline, Figure 5) and
studied as neurogenic agents in models of acute and chronic neurological diseases, such as traumatic
brain injury [125], Down syndrome [126], Parkinson disease [127], and ALS [128]. Mechanistic studies
have demonstrated that the neurogenic actions of P7C3 and its derivatives are due to the activation of
the NAMPT-NAD cascade [129].
Consequently, there is sufficient evidence supporting the NAMPT-NAD pathway as a valid target
in restoring neurogenesis. On the other hand, the potential of this kind of compounds should be further
evaluated in order to understand the effects of improving neurogenic processes in acute, chronic and
degenerative neurological diseases.
7. Role of the Transcription Factor Nrf2 in Neurogenesis
The nuclear erythroid 2-related factor (Nrf2) is a transcription factor that regulates survival
genes and the production of antioxidant enzymes. In non-stressed conditions, Nrf2 is mainly located
in the cytosol, where its constitutive low levels are strictly controlled by the proteasome [130].
Under pathological conditions (oxidative stress, toxic insults, etc.) the Nrf2 proteolytic degradation
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is diminished, leading to Nrf2 accumulation in the cytosol and its further translocation to the
nucleus. Nuclear Nrf2 binds to the antioxidant response elements (AREs), which are common
promoters in many cytoprotective genes, inducing the expression of defence proteins such as
NAD(P)H-quinone oxidoreductase 1 (NQO1), glutathione-S-transferase, and heme oxygenase-1
(HO-1), among others [131].
Studies in Nrf2-knockout mice have demonstrated that loss of the Nrf2-AREs signalling pathway
increases vulnerability to toxic conditions, due to failures in the self-protective responses [132].
Moreover, human epidemiological studies have revealed a link between Nrf2 mutations and the
risk of suffering many pathologies, including degenerative diseases [133].
In addition to its pivotal role in the endogenous defence, Nrf2 is an important player in the
regulation of neurogenesis. Overexpression of Nrf2 and its downstream genes increased neuronal cell
proliferation and differentiation in the human neuroblastoma cell line SH-SY5Y and in rat NSC-derived
neurospheres [134,135]. The above data support the use of activators of the Nrf2-AREs signalling
pathway, such as curcumin and resveratrol, as neurogenic agents for the treatment of neurological
diseases. It is important to note that in addition to the Nrf2 activation, these phytochemicals may trigger
other interconnected pathways and, as a result, their mechanisms of action are certainly complex.
Curcumin [(1E,6E)-1,7-bis(4-hydroxy-3-methoxyphenyl)-1,6-heptadiene-3,5-dione] is the major
phenolic component of yellow curry, which is extracted from the rhizomes of Curcuma longa and
is widely used in Asian cooking and traditional medicine (Figure 6). Curcumin is a lipophilic
compound that easily penetrates into the CNS and reaches its maximal concentrations in hippocampus,
although it also suffers a rapid metabolism and excretion [136]. This low bioavailability has led to the
synthesis of curcumin derivatives with improved pharmacokinetics [137,138], or to the development
of nano-formulations that considerably prolonged the curcumin’s half-life in cerebral cortex and
hippocampus [136].
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In in vitro experiments, Kang et al. found that curcumin induced the generation of new neurons,
the formation of new synaptic networks and the migration of neural progenitors in brain-derived
adult NSCs. Curcumin promoted NSC-differentiation to neurons, but not to astrocytes [139]. In a
combination of in vitro and in vivo experiments, Kim et al. have demonstrated that curcumin increases
the proliferation of embryonic cortical NSCs in cultures and the number of newly generated cells in
the DG of the hippocampus in adult mice. Interestingly, low concentrations of curcumin (500 nM)
stimulated the proliferation of embryonic cortical NSCs, whereas concentrations above 10 µM were
cytotoxic and inhibited NSC growth [140].
The therapeutic potential of curcumin has been probed in cellular and animal models of different
pathologies, including neurodegenerative disorders [137,141]. In a murine AD-model, curcumin
inhibited the formation and aggregation of Aβ oligomers and fibrils, disrupted existing amyloid
plaques, and partially restored damaged neurites [142].
Based on these interesting findings, curcumin has also tested in humans. In a six-month pilot
clinical trial in AD-patients, curcumin (1 g once daily) did not cause side effects; raised plasmatic
vitamin E, due to its antioxidant properties; and slightly increased serum Aβ, possibly reflecting the
ability of curcumin to disaggregate amyloid deposits in the brain [143].
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Resveratrol (trans-3,5,4′-trihydroxystilbene, Figure 6) is a natural polyphenol produced by several
plants as a defence mechanism against pathogens, such as bacteria and fungi. Red grapes and red
wine are rich in this nutraceutical that is believed to be the main promoter of the “French paradox”:
a low incidence of coronary heart diseases in people who have a relatively rich diet in cholesterol and
saturated fats, but moderate consumption of red wine [144]. Like curcumin, resveratrol can cross the
blood-brain barrier to reach its cerebral targets, but it is also rapidly metabolised [145]. To overcome
this problem new formulations have been probed, being one of the most recent the nanoencapsulation
with chitosan and γ-poly(glutamic acid) that improve the solubility, stability, and bioavailability of
resveratrol [146]. Moreover, a current active field is the research of resveratrol-based derivatives with
improved pharmacokinetics, some of them in clinical studies for different therapeutic uses [147,148].
The effects of resveratrol on neurogenic processes show a dual pattern depending on the dose,
as shown by Kumar et al. using in vitro and in vivo experiments. In cultured embryonic NSC derived
from Wistar rats, resveratrol increased cell proliferation at low concentration (10 µM), whereas it
exhibited inhibitory effects at high proportions (>20 µM). In adult rats, administration of resveratrol
(20 mg/kg body weight) increased the number of new cells in hippocampus [149].
Moreover, Torres-Pérez et al. found that in Balb/C mice, a rodent strain with low baseline levels
of adult neurogenesis, the treatment with resveratrol during two weeks increased hippocampal cell
survival and NSC proliferation, improving hippocampal plasticity and memory performance [150].
Resveratrol was tested in models of a variety of pathologies, including stress, depression,
ethanol-induced toxicity, chronic fatigue, stroke, and neurodegenerative diseases [151]. In a cellular
AD-model of hippocampal tissue treated with Aβ, Rege et al. found that resveratrol protected
cells from oxidative damage, by attenuating lipid peroxidation and increasing levels of endogenous
antioxidants, such as glutathione reductase, catalase, superoxide dismutase, tocopherol, and ascorbic
acid. Interestingly, resveratrol also amplified the expression of memory-related synaptic proteins,
attenuating this AD-symptom in vitro [152].
In an in vitro model of stroke using oxygen-glucose deprivation/reoxygenation (OGD/R),
resveratrol increased NSCs proliferation and survival in a concentration-dependent manner [153].
Furthermore, in rats subjected to a focal cerebral ischemia, resveratrol was found to be a plasticity
inducer through the upregulation of Nrf-2 and HO-1 [154].
Resveratrol was tested in patients with mild to moderate AD in a double-blind, placebo-controlled
trial, being safe and well-tolerated. This phytochemical and its metabolites were detected in the CNS,
verifying they cross the blood-brain barrier. Unexpectedly, resveratrol increased the brain volume
loss, but this effect was not associated with cognitive or functional decline. To determine whether
resveratrol would be beneficial in AD treatments, alone or in combination with other drugs, larger
clinical studies are required [155].
8. Conclusions
The discovery of the existence of stem cell niches in the adult human brain has stimulated the
research of the therapeutic potential of the regenerative medicine for the treatment of CNS-pathologies.
Replacement of damaged neural tissues by healthy cells would be a breakthrough for the therapy of
many acute, chronic, or degenerative diseases. However, adult neurogenesis is a complex process
that involves a myriad of mediators, such as transcription and epigenetic factors, signalling pathways,
growth factors, neurotransmitters, and hormones. Current efforts are devoted to characterize the
relevance, extent and significance of neurogenesis in the adult brain, and to determine whether the
pharmacological stimulation of the underlying processes can address one of the toughest challenges in
therapeutics: the possibility of replacing damaged neuronal tissue by functional de novo neuronal
bodies fully integrated in the CNS-circuitry. In this effort, small molecules may play a central role as
potential candidates to become brain-restoring drugs and/or pharmacological tools that intervene at
different levels of neurogenic pathways. However, a number of challenges derived from the scarcity
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of neurogenic niches in adult human brain and the complexity of the involved processes need to be
addressed before neurogenic-stimulating small-molecules can be used in the common medical practice.
The good news are related to the diversity of targets that seem to be involved in adult neurogenesis,
as well as the diversity of chemical scaffolds able to intervene in these processes. Thus, there is a vast
field for the design and synthesis of new neurogenic small molecules as potential drugs for neurological
diseases or as pharmacological tools for unravelling molecular mechanisms of adult neurogenesis.
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